CordIn is Gamida Cell’s curative treatment for rare genetic diseases, including blood diseases such as sickle cell disease (SCD) and thalassemia, bone marrow failure syndromes such as aplastic anemia, genetic metabolic diseases.
Data to date has been encouraging, showing successful and rapid engraftment and cure of disease symptoms in these hard to engraft patients. Thus, the product appears to overcome the engraftment barriers of umbilical cord blood and has the potential to increase access to curative transplantation for SCD.
CordIn is currently being evaluated in a Phase 1/2 study in patients with sickle cell disease, a rare genetic disease of red blood cells.
The Company is also currently enrolling patients in an investigator-initiated study of Cordin for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. The study is being conducted by Dr. Richard W. Childs, Clinical Director of the National Heart, Lung, and Blood Institute’s (NHLBI) Division of Intramural Research in the National Institutes of Health (NIH) and Assistant United States Surgeon General.